Risks of miscarriage and inadvertent exposure to artemisinin derivatives in the first trimester of pregnancy: A prospective cohort study in western Kenya

Malaria Journal

Volumn 14, Issue 1, 2015, Pages

  Dellicour, Stephanie ^a   Desai, Meghna ^b   Aol, George ^c   Oneko, Martina ^c   Ouma, Peter ^c   Bigogo, Godfrey ^c   Burton, Deron C ^b   Breiman, Robert F ^d   Hamel, Mary J ^b   Slutsker, Laurence ^b   Feikin, Daniel ^b   Kariuki, Simon ^c   Odhiambo, Frank ^c   Pandit, Jayesh ^e   Laserson, Kayla F ^b   Calip, Greg ^f   Stergachis, Andy ^g   Ter Kuile, Feiko O ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^d EMORY UNIVERSITY   (United States)

^e Bayer Healthcare   (Kenya)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Anti malarials; Drug safety in pregnancy; Miscarriage; Pharmacovigilance; Teratogenicity

Indexed keywords

ARTEMISININ DERIVATIVE; QUININE; ANTIMALARIAL AGENT; ARTEMISININ;

ADOLESCENT; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HEALTH SURVEY; HUMAN; KENYA; MALARIA; OBSERVATIONAL STUDY; PREGNANCY OUTCOME; PROSPECTIVE STUDY; RISK FACTOR; SPONTANEOUS ABORTION; ABORTION, SPONTANEOUS; CHEMICALLY INDUCED; MIDDLE AGED; PREGNANCY; RISK ASSESSMENT; YOUNG ADULT;

ABORTION, SPONTANEOUS; ADOLESCENT; ADULT; ANTIMALARIALS; ARTEMISININS; FEMALE; HUMANS; KENYA; MIDDLE AGED; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PROSPECTIVE STUDIES; RISK ASSESSMENT; YOUNG ADULT;

EID: 84960115503     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-015-0950-6     Document Type: Article

References (35)

1. WHO. World Malaria Report: 2013. Geneva: World Health Organization 2013.
2. Phillips-Howard PA, Steffen R, Kerr L, Vanhauwere B, Schildknecht J, Fuchs E, et al. Safety of mefloquine and other antimalarial agents in the first trimester of pregnancy. J Travel Med. 1998;5:121-6.
3. Phillips-Howard PA, Wood D. The safety of antimalarial drugs in pregnancy. Drug Saf. 1996;14:131-45.
4. Clark RL. Embryotoxicity of the artemisinin antimalarials and potential consequences for use in women in the first trimester. Reprod Toxicol. 2009;28:285-96.
5. WHO, TDR. Assessment of the safety of artemisinin compounds in pregnancy: report of two joint informal consultations convened in 2006. Geneva: World Health Organization 2007.
6. Clark R, Kumemura M, Makori N, Nakata Y, Bernard F, Harrell A, et al. Artesunate: developmental toxicity in monkeys. Bir Birth Defects Research (Part A). 2006;76:329.
7. Kelemen E, Calvo W, Fliedner T. Atlas of Human Hemopoietic Development. Berlin: 1979.
8. White TE, Clark RL. Sensitive periods for developmental toxicity of orally administered artesunate in the rat. Birth Defects Res B Dev Reprod Toxicol. 2008;83:407-17.
9. Adam I, Elhassan EM, Omer EM, Abdulla MA, Mahgoub HM, Adam GK. Safety of artemisinins during early pregnancy, assessed in 62 Sudanese women. Ann Trop Med Parasitol. 2009;103:205-10.
10. Deen JL, von Seidlein L, Pinder M, Walraven GE, Greenwood BM. The safety of the combination artesunate and pyrimethamine-sulfadoxine given during pregnancy. Trans R Soc Trop Med Hyg. 2001;95:424-8.
11. Dellicour S, Hall S, Chandramohan D, Greenwood B. The safety of artemisinins during pregnancy: a pressing question. Malar J. 2007;6:15.
12. Manyando C, Mkandawire R, Puma L, Sinkala M, Mpabalwani E, Njunju E, et al. Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia. Malar J. 2010;9:249.
13. McGready R, Lee SJ, Wiladphaingern J, Ashley EA, Rijken MJ, Boel M, et al. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis. 2012;12:388-96.
14. Mosha D, Mazuguni F, Mrema S, Sevene E, Abdulla S, Genton B. Safety of artemether-lumefantrine exposure in first trimester of pregnancy: an observational cohort. Malar J. 2014;13:197.
15. Rulisa S, Kaligirwa N, Agaba S, Karema C, Mens PF, de Vries PJ. Pharmacovigilance of artemether-lumefantrine in pregnant women followed until delivery in Rwanda. Malar J. 2012;11:225.
16. WHO. Assessment of the safety of artemisinin compounds in pregnancy. Report of two informal consultations convened by WHO in 2002. Geneva: World Health Organization; 2003.
17. WHO. Guidelines for the treatment of malaria. Third edition. Geneva: World Health Organization; 2015.
18. Dellicour S, ter Kuile FO, Stergachis A. Pregnancy exposure registries for assessing antimalarial drug safety in pregnancy in malaria-endemic countries. PLoS Med. 2008;5:e187.
19. Huynh BT, Fievet N, Gbaguidi G, Dechavanne S, Borgella S, Guezo-Mevo B, et al. Influence of the timing of malaria infection during pregnancy on birth weight and on maternal anemia in Benin. Am J Trop Med Hyg. 2011;85:214-20.
20. Cottrell G, Mary JY, Barro D, Cot M. The importance of the period of malarial infection during pregnancy on birth weight in tropical Africa. Am J Trop Med Hyg. 2007;76:849-54.
21. Odhiambo FO, Laserson KF, Sewe M, Hamel MJ, Feikin DR, Adazu K, et al. Profile: the KEMRI/CDC Health and Demographic Surveillance System-Western Kenya. Int J Epidemiol. 2012;41:977-87.
22. Bigogo G, Audi A, Aura B, Aol G, Breiman RF, Feikin DR. Health-seeking patterns among participants of population-based morbidity surveillance in rural western Kenya: implications for calculating disease rates. Int J Infect Dis. 2010;14:e967-73.
23. Feikin DR, Audi A, Olack B, Bigogo GM, Polyak C, Burke H, et al. Evaluation of the optimal recall period for disease symptoms in home-based morbidity surveillance in rural and urban Kenya. Int J Epidemiol. 2010;39:450-8.
24. McKenzie D. Measuring inequality with asset indicators. Journal of Population Economics. 2005;18:229.
25. Sonis J. A closer look at confounding. Fam Med. 1998;30:584-8.
26. Kleinbaum DG, Klein M. Chapter 6: Modeling Strategy Guidelines. Logistic Regression: A Self-Learning Text. 3rd edition ed.: Springer; 2010.
27. Radeva-Petrova D, Kayentao K, ter Kuile FO, Sinclair D, Garner P. Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment. Cochrane Database Syst Rev. 2014;10:CD000169.
28. Sangaré L, Weiss N, Brentlinger P, Richardson B, Staedke S, Kiwuwa M, et al. Patterns of antimalarial drug treatment among pregnant women in Uganda. Malar J. 2011;10:152.
29. Achan J, Talisuna AO, Erhart A, Yeka A, Tibenderana JK, Baliraine FN, et al. Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. Malar J. 2011;10:144.
30. Piola P, Nabasumba C, Turyakira E, Dhorda M, Lindegardh N, Nyehangane D, et al. Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial. Lancet Infect Dis. 2010;10:762-9.
31. Clark RL. Effects of artemisinins on reticulocyte count and relationship to possible embryotoxicity in confirmed and unconfirmed malarial patients. Birth Defects Res A Clin Mol Teratol. 2012;94:61-75.
32. Newton PN, Green MD, Mildenhall DC, Plancon A, Nettey H, Nyadong L, et al. Poor quality vital anti-malarials in Africa - an urgent neglected public health priority. Malar J. 2011;10:352.
33. Jong De, van den Berg LT, Feenstra N, Sorensen HT, Cornel MC. Improvement of drug exposure data in a registration of congenital anomalies. Pilot-study: pharmacist and mother as sources for drug exposure data during pregnancy. EuroMAP Group. Europen Medicine and Pregnancy Group. Teratology. 1999;60:33-6.
34. Rockenbauer M, Olsen J, Czeizel AE, Pedersen L, Sorensen HT, Euro MAPG. Recall bias in a case-control surveillance system on the use of medicine during pregnancy. Epidemiology. 2001;12:461-6.
35. de Jong-van den Berg LT, Waardenburg CM, Haaijer-Ruskamp FM, Dukes MN, Wesseling H. Drug use in pregnancy: a comparative appraisal of data collecting methods. Eur J Clin Pharmacol. 1993;45:9-14.